

# Resource Summary Report

Generated by [RRID](#) on Aug 8, 2026

## Foundation Medicine

RRID:SCR\_025628

Type: Tool

### Proper Citation

Foundation Medicine (RRID:SCR\_025628)

### Resource Information

**URL:** <https://www.foundationmedicine.com/>

**Proper Citation:** Foundation Medicine (RRID:SCR\_025628)

**Description:** American company based in Cambridge, Massachusetts, which develops, manufactures, and sells genomic profiling assays based on next-generation sequencing technology for solid tumors, hematologic malignancies, and sarcomas. Specializes in precision medicine. FMI routinely analyzes cancer specimens using advanced sequencing technology of FoundationOne to profile tumor genomics.

**Abbreviations:** FMI

**Synonyms:** Inc., Foundation Medicine

**Resource Type:** commercial organization

**Keywords:** genomic profiling assays, next-generation sequencing technology, solid tumors, hematologic malignancies, sarcomas, profile tumor genomics,

**Resource Name:** Foundation Medicine

**Resource ID:** SCR\_025628

**Record Creation Time:** 20240816T053258+0000

**Record Last Update:** 20260808T190729+0000

### Ratings and Alerts

No rating or validation information has been found for Foundation Medicine.

No alerts have been found for Foundation Medicine.

### Data and Source Information

## Usage and Citation Metrics

We found 14 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Gensheimer MF, et al. (2026) Creating strong predictive models in oncology. Patterns (New York, N.Y.), 7(2), 101492.

Liang J, et al. (2026) Loss of luminal lineage drives resistance to next-generation ER?? antagonists in pretreated ER+ HER2- locally-advanced or metastatic breast cancer. Nature communications, 17(1).

Yemelyanenko J, et al. (2026) C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3. Cancer research, 86(6), 1372.

Millan B, et al. (2025) Molecular Genetics of Renal Cell Carcinoma: A Narrative Review Focused on Clinical Relevance. Current oncology (Toronto, Ont.), 32(6).

Pietrantonio F, et al. (2025) The Prostaglandin EP4 Antagonist Vorbipirant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(4), 649.

Jackson H, et al. (2025) MarkerDB 2.0: a comprehensive molecular biomarker database for 2025. Nucleic acids research, 53(D1), D1415.

Li W, et al. (2025) Analytical validation of a homologous recombination deficiency signature (HRDsig) in pan-tumor tissue samples. PloS one, 20(11), e0336940.

Nikanjam M, et al. (2025) Novel clinical trial designs emerging from the molecular reclassification of cancer. CA: a cancer journal for clinicians, 75(3), 243.

Louie BH, et al. (2024) Molecular Tumor Board for Unicorns: Outcomes for rare and ultra-rare cancers using an N-of-One personalized treatment strategy. iScience, 27(8), 110465.

Mostafa G, et al. (2024) The power of deep learning in simplifying feature selection for hepatocellular carcinoma: a review. BMC medical informatics and decision making, 24(1), 287.

Martini G, et al. (2023) Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial. Frontiers in oncology, 13, 1069370.

Persha HE, et al. (2022) Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response. Journal of hematology & oncology, 15(1), 119.

Cheng S, et al. (2022) Utilizing Liquid Biopsy for Treatment Management in Bone-Dominant Metastatic Breast Cancer: A Case Report. *Case reports in oncology*, 15(3), 854.

Akhoundova D, et al. (2022) Targeting ALK in Neuroendocrine Tumors of the Lung. *Frontiers in oncology*, 12, 911294.